Download PDF
Horm Metab Res 2020; 52(05): 298-304
DOI: 10.1055/a-1151-2342
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

FGF23 Beyond the Kidney: A New Bone Mass Regulator in the General Population

Stefana Catalina Bilha
1   Endocrinology Department, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
,
Andrei Bilha
2   Physiology Department, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
,
Maria-Christina Ungureanu
1   Endocrinology Department, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
,
Anca Matei
1   Endocrinology Department, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
,
Alexandru Florescu
1   Endocrinology Department, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
,
Cristina Preda
1   Endocrinology Department, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
,
Adrian Covic
3   Nephrology Department, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
,
Dumitru Branisteanu
1   Endocrinology Department, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
› Author Affiliations Funding: Universitatea de Medicina și Farmacie Grigore T. Popa, Iasi, Grant No.: 31587/23.12.2015
Further Information

Publication History

received 08 May 2019

accepted 25 March 2020

Publication Date:
13 May 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Clinical studies investigating the relationship between fibroblast growth factor 23 (FGF23) and bone mass are controversial, especially in the healthy renal population. Our study is one of the forefronts investigating the relationship between FGF23 and bone mass parameters in the general population, according to age, sex, menopausal, and nutritional status. Cross-sectional study enrolling 123 volunteers between 20–80 years of age without primary osteoporosis under treatment nor secondary osteoporosis, where bone mass (bone mineral density-BMD, bone mineral content-BMC; assessed by Dual X-Ray Absorptiometry-DXA), body composition (DXA evaluation), and also the serum levels of FGF23, parathormone (PTH), 25(OH)D, bone resorption marker C-terminal telopeptide of type I collagen (CTx) and leptin were determined. FGF23 was negatively and independently associated with BMD and/or BMC in all groups. FGF23 contributed to up to 10% (p <0.05) of femoral neck BMD variance in postmenopausal women, but was not an accurate discriminator of normal versus low bone mass (AUC=0.622±0.076). FGF23 did not correlate with 25(OH)D, CTx, body weight, body composition parameters or leptin. FGF23 was independently associated with PTH in premenopausal women and men only. FGF23 was negatively associated with bone mass parameters in both sexes, but was not a fine discriminator between normal bone mass and osteopenia/osteoporosis. The mechanism through which FGF23 acts upon the bone seems independent of the nutritional status, requiring further investigation.

Key words

FGF23 - bone / calcium homeostasis - osteoporosis, osteopenia
 

  • References

  • 1 Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord 2015; 16: 165-174
    CrossrefPubMedGoogle Scholar
  • 2 Kawai M. The FGF23/Klotho axis in the regulation of mineral and metabolic homeostasis. Horm Mol Biol Clin Investig 2016; 28: 55-67
    PubMedGoogle Scholar
  • 3 Juppner H, Wolf M, Salusky IB. FGF-23: More than a regulator of renal phosphate handling?. J Bone Min Res 2010; 25: 2091-2097
    CrossrefPubMedGoogle Scholar
  • 4 Michigami T. Extracellular phosphate as a signaling molecule. Contrib Nephrol 2013; 180: 14-24
    PubMedGoogle Scholar
  • 5 Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol 2010; 25: 603-608
    CrossrefPubMedGoogle Scholar
  • 6 Saini RK, Kaneko I, Jurutka PW. et al. 1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif Tissue Int 2013; 92: 339-353
    CrossrefPubMedGoogle Scholar
  • 7 Wang H, Yoshiko Y, Yamamoto R. et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008; 23: 939-948
    CrossrefPubMedGoogle Scholar
  • 8 Andrukhova O, Streicher C, Zeitz U. et al. FGF23 and parathyroid hormone signaling interact in kidney and bone. Mol Cell Endocrinol 2016; 436: 224-239
    CrossrefPubMedGoogle Scholar
  • 9 Komaba H, Kaludjerovic J, Hu DZ. et al. Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int 2017; 92: 599-611
    CrossrefPubMedGoogle Scholar
  • 10 Shen J, Fu S, Song Y. Relationship of fibroblast growth factor 23 (FGF-23) serum levels with low bone mass in postmenopausal women. J Cell Biochem 2017; 118: 4454-4459
    CrossrefPubMedGoogle Scholar
  • 11 Imel EA, Liu Z, McQueen AK. et al. Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone 2016; 86: 98-105
    CrossrefPubMedGoogle Scholar
  • 12 Jovanovich A, Bùzková P, Chonchol M. et al. Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: The cardiovascular health study. J Clin Endocrinol Metab 2013; 98: 3323-3331
    CrossrefPubMedGoogle Scholar
  • 13 Mirza M, Karlsson MK, Mellstrom D. et al. Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Min Res 2011; 26: 857-864
    CrossrefPubMedGoogle Scholar
  • 14 Grethen E, Hill KM, Jones R. et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab 2012; 97: 1655-1662
    CrossrefPubMedGoogle Scholar
  • 15 Watts NB, Bilezikian JP, Camacho PM. et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pr 2010; 16: 1-37
    PubMedGoogle Scholar
  • 16 Liu S, Tang W, Fang J. et al. Novel Regulators of Fgf23 expression and mineralization in hyp bone. Mol Endocrinol 2009; 23: 1505-1518
    CrossrefPubMedGoogle Scholar
  • 17 Carrillo-López N, Panizo S, Alonso-Montes C. et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 2016; 90: 77-89
    CrossrefPubMedGoogle Scholar
  • 18 Isakova T, Wahl P, Vargas GS. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378
    CrossrefPubMedGoogle Scholar
  • 19 Wesseling-Perry K, Pereira RC, Wang H. et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517
    CrossrefPubMedGoogle Scholar
  • 20 Manghat P, Fraser WD, Wierzbicki AS. et al. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 2010; 21: 1853-1861
    CrossrefPubMedGoogle Scholar
  • 21 Kanaan N, Claes K, Devogelaer JP. et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol 2010; 5: 1887-1892
    CrossrefPubMedGoogle Scholar
  • 22 Desjardins L, Liabeuf S, Renard C. et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012; 23: 2017-2025
    CrossrefPubMedGoogle Scholar
  • 23 Wu Q, Xiao DM, Fan WF. et al. Effect of serum fibroblast growth factor-23, matrix gla protein and fetuin-a in predicting osteoporosis in maintenance hemodialysis patients. Ther Apher Dial 2014; 18: 427-433
    CrossrefPubMedGoogle Scholar
  • 24 Yilmaz VT, Ozdem S, Donmez L. et al. FGF-23, a-klotho gene polymorphism and their relationship with the markers of bone metabolism in chronic peritoneal dialysis patients. Eurasian J Med 2015; 47: 115-125
    CrossrefPubMedGoogle Scholar
  • 25 Park SY, Jeong KH, Moon JY. et al. The relationship between circulating Fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients. Clin Exp Nephrol 2010; 14: 239-243
    CrossrefPubMedGoogle Scholar
  • 26 Han W, Bai X, Han L. et al. The relationship between serum fibroblast growth factor 23, Klotho, and lumbar spine bone mineral density in northern Chinese postmenopausal women. Menopause 2018; 26: 546-553
    PubMedGoogle Scholar
  • 27 Holecki M, Chudek J, Wiȩcek A. et al. The serum level of fibroblast growth factor-23 and calcium-phosphate homeostasis in obese perimenopausal women. Int J Endocrinol 2011; 2011; 707126
    PubMedGoogle Scholar
  • 28 Marsell R, Mirza M, Mallmin H. et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int 2009; 20: 1167-1173
    CrossrefPubMedGoogle Scholar
  • 29 Lane NE, Parimi N, Corr M. et al. Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: The Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res 2013; 28: 2325-2332
    CrossrefPubMedGoogle Scholar
  • 30 Pekkinen M, Laine CM, Mäkitie R. et al. FGF23 gene variation and its association with phosphate homeostasis and bone mineral density in Finnish children and adolescents. Bone 2015; 71: 124-130
    CrossrefPubMedGoogle Scholar
  • 31 Sridharan M, Cheung J, Moore AE. et al. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: Association with biomarker of bone formation. Calcif Tissue Int 2010; 87: 398-405
    CrossrefPubMedGoogle Scholar
  • 32 Samadfam R, Richard C, Nguyen-Yamamoto L. et al. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009; 150: 4835-4845
    CrossrefPubMedGoogle Scholar